PSNL News and Press, Personalis Inc. From 02/09/23

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast t...

The shares of Personalis, Inc. ( NASDAQ: PSNL ) gained for the fifth straight session on Monday after Needham upgraded the cancer genomics company to Buy from Hold, arguing that stock is “significantly undervalued” despite the recent gains. Personalis ( PSNL ) has mo...

Main Tips for Buying Penny Stocks Right Now Penny stocks have been a popular investment option for many years, offering the potential for high returns at a relatively low cost. With the stock market constantly fluctuating, penny stocks can offer a great opportunity for those looking to ma...

Personalis ( NASDAQ: PSNL ) and Moderna ( NASDAQ: MRNA ) said they had signed a new agreement to continue using the PSNL's NeXT Platform as part of upcoming clinical studies testing cancer vaccine mRNA-4157/V940, jointly developed by Moderna and Merck ( MRK ). The plat...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis Ne...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Summary Personalis is a small-cap cancer genomics company with a next-gen cancer diagnostics platform whose stock has lost over 80% of its value over the past twelve months. Personalis is reporting substantial losses, however, the company’s strong balance sheet could provide them...

Shares of Personalis ( NASDAQ: PSNL ) rose 10% after the bell on Wednesday after it forecasted fourth quarter revenue of about $16.7 million, and said it expects full-year revenue of $65 million, above its previously provided range of $63 million to $64 million. The Seeki...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022. Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and appr...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West...